These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 16430197)

  • 1. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
    Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.
    Viganò A; Brambilla P; Cafarelli L; Giacomet V; Borgonovo S; Zamproni I; Zuccotti G; Mora S
    Antivir Ther; 2007; 12(3):297-302. PubMed ID: 17591019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.
    Madruga JR; Cassetti I; Suleiman JM; Etzel A; Zhong L; Holmes CB; Cheng AK; Enejosa J;
    HIV Clin Trials; 2007; 8(6):381-90. PubMed ID: 18042503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
    Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
    AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
    Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
    JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
    Havlir DV; Koelsch KK; Strain MC; Margot N; Lu B; Ignacio CC; Miller MD; Wong JK;
    J Infect Dis; 2005 Apr; 191(7):1164-8. PubMed ID: 15747253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
    HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
    Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V;
    Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
    Girard PM; Cabié A; Michelet C; Verdon R; Katlama C; Mercié P; Morand-Joubert L; Pétour P; Monchecourt F; Chêne G; Trylesinski A;
    J Antimicrob Chemother; 2009 Jul; 64(1):126-34. PubMed ID: 19403652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
    Anastos K; Lu D; Shi Q; Tien PC; Kaplan RC; Hessol NA; Cole S; Vigen C; Cohen M; Young M; Justman J
    J Acquir Immune Defic Syndr; 2007 May; 45(1):34-42. PubMed ID: 17460470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
    Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
    Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.
    Arrizabalaga J; Arazo P; Aguirrebengoa K; García-Palomo D; Chocarro A; Labarga P; Muñoz-Sánchez MJ; Echevarría S; Oteo JA; Uriz J; Letona S; Fariñas MC; Peralta G; Pinilla J; Ferrer P; Alvarez ML; Iribarren JA
    HIV Clin Trials; 2007; 8(5):328-36. PubMed ID: 17956834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
    Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
    Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G;
    AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
    Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S
    HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.